Natus Medical (BABY) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Natus Medical (NASDAQ:BABY) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

A number of other research analysts have also recently commented on the company. ValuEngine upgraded Natus Medical from a sell rating to a hold rating in a research note on Monday, April 1st. BidaskClub cut Natus Medical from a hold rating to a sell rating in a research note on Friday, February 8th. Finally, William Blair restated a market perform rating on shares of Natus Medical in a research note on Saturday, January 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. Natus Medical has a consensus rating of Hold and a consensus price target of $36.00.

Shares of BABY opened at $24.04 on Tuesday. The stock has a market cap of $799.85 million, a price-to-earnings ratio of 16.93 and a beta of 0.52. Natus Medical has a 12 month low of $23.58 and a 12 month high of $37.95. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.54 and a current ratio of 2.14.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, February 13th. The medical equipment provider reported $0.43 EPS for the quarter, missing the Zacks’ consensus estimate of $0.50 by ($0.07). The company had revenue of $141.00 million for the quarter, compared to analyst estimates of $135.80 million. Natus Medical had a positive return on equity of 11.64% and a negative net margin of 4.32%. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.42 EPS. As a group, equities research analysts predict that Natus Medical will post 1.25 earnings per share for the current fiscal year.

In other Natus Medical news, Director Robert A. Gunst sold 8,304 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $28.09, for a total transaction of $233,259.36. Following the transaction, the director now owns 32,392 shares in the company, valued at $909,891.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Robert A. Gunst sold 6,304 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $27.96, for a total value of $176,259.84. Following the transaction, the director now owns 32,392 shares in the company, valued at approximately $905,680.32. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of BABY. Vaughan Nelson Investment Management L.P. acquired a new position in shares of Natus Medical in the fourth quarter worth about $33,985,000. Norges Bank acquired a new position in shares of Natus Medical in the fourth quarter worth about $11,884,000. BlackRock Inc. lifted its stake in shares of Natus Medical by 4.6% in the third quarter. BlackRock Inc. now owns 5,013,693 shares of the medical equipment provider’s stock worth $178,739,000 after acquiring an additional 220,521 shares in the last quarter. Morgan Stanley lifted its stake in shares of Natus Medical by 168.9% in the third quarter. Morgan Stanley now owns 200,720 shares of the medical equipment provider’s stock worth $7,157,000 after acquiring an additional 126,079 shares in the last quarter. Finally, Rutabaga Capital Management LLC MA lifted its stake in shares of Natus Medical by 39.5% in the fourth quarter. Rutabaga Capital Management LLC MA now owns 362,867 shares of the medical equipment provider’s stock worth $12,348,000 after acquiring an additional 102,791 shares in the last quarter. Institutional investors own 99.22% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: How do taxes affect a CDs total return?

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.